The prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs: British Society for Rheumatology guideline scope (2024)
Journal Article
Mercer, L., Abhishek, A., Kavirayani, A., Ahmed, A., Davidson, A., Foulkes, A., Jones, C., Nash, C., Rose-Parfitt, E., Dhillon, E., Zabate, G., Twohig, H., De Vere, H., Scott, J., Reynolds, J., Holmes, J., Hartley, K., Warrier, K., Nowak, K., Parsons, K., …Galloway, J. (in press). The prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs: British Society for Rheumatology guideline scope. Rheumatology Advances in Practice, 8(3), Article rkae077. https://doi.org/10.1093/rap/rkae077

Lay Summary: What does this mean for patients? A revised guideline, produced by the British Society for Rheumatology (BSR), will provide up-to-date information about the safe prescribing and monitoring of the effects of non-biologic (or conventional... Read More about The prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs: British Society for Rheumatology guideline scope.

Exploring a Gemcitabine-Glucose Hybrid as a Glycoconjugate Prodrug (2024)
Journal Article
Porter, J., Noble, A. R., Signoret, N., Fascione, M. A., & Miller, G. J. (in press). Exploring a Gemcitabine-Glucose Hybrid as a Glycoconjugate Prodrug. ACS Omega, 9(29), 31703-31713. https://doi.org/10.1021/acsomega.4c02417

Nucleoside analogues are established treatments for cancer and viral infection. Gemcitabine is a commonly employed nucleoside analogue displaying anticancer properties against a range of tumor types but is rapidly inactivated in vivo. Efforts to bols... Read More about Exploring a Gemcitabine-Glucose Hybrid as a Glycoconjugate Prodrug.